New combo attack shows promise for Oligo-Metastatic lung cancer
NCT ID NCT03965468
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests a combination of immunotherapy (durvalumab), chemotherapy (carboplatin and paclitaxel), and targeted radiation to metastatic spots, followed by surgery or radiation to the main lung tumor. The goal is to see if this aggressive approach can keep the cancer from growing for at least a year in people with non-small cell lung cancer that has spread to only a few other sites. The study enrolled 96 participants and is no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Durvalumab (Imfinzi), Carboplatin, Paclitaxel
What this could lead to
If successful, this combination approach could improve control of advanced lung cancer that has spread to a few other sites, potentially extending life without progression.
What could go wrong
This is a mid-stage trial with only 96 participants and no comparison group, so results may not be definitive. Side effects from chemotherapy, immunotherapy, and radiation can be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne, Switzerland
-
Erasmus Medical Centre
Rotterdam, Netherlands
-
European Institute of Oncology
Milan, Italy
-
Geneva University Hospital
Geneva, Switzerland
-
Hosp. De la Santa Creu i Sant Pau
Barcelona, Spain
-
Hosp. Sanchinarro- Centro Integral Oncología Clara Campal
Madrid, Spain
-
Hosp. Uni. Politécnico La Fe
Valencia, Spain
-
Hosp. Uni. Virgen de las Nieves
Granada, Spain
-
IRCCS Istituto Nazionale Tumori Regina Elena
Roma, Italy
-
Inselspital Bern
Bern, Switzerland
-
Istituto Oncologico Veneto - Irccs
Padova, Italy
-
Kantonsspital Winterthur
Winterthur, Switzerland
-
Maastricht University Medical Center
Maastricht, Netherlands
-
University Hospital Zurich
Zurich, Switzerland
-
Vall d'Hebron University Hospital
Madrid, Spain